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Clinical studies of non-myeloablative allogeneic hemato-
poietic SCT (NST) have demonstrated that donor lympho-
cytes transferred with the graft may produce a clinically
meaningful antitumor effect (graft-versus tumor) in reci-
pients with renal cell cancer or other solid tumors
refractory to conventional treatments.1,2 Few data are
currently available in this ﬁeld in patients with medullo-
blastoma. Matsuda et al.3 reported one child who obtained
a short-lasting PR following allogeneic hematopoietic SCT
for relapsed medulloblastoma. Lundberg et al.4 reported
one patient who achieved CR lasting more than 2 years
following allogeneic hematopoietic SCT for recurrent
metastatic medulloblastoma. However, a clear graft-versus
tumor effect cannot be ruled out in these patients as they
received myeloablative high doses of chemotherapy as the
conditioning regimen, which might per se be responsible for
tumor response. In this article, we report a durable
complete tumor response following NST in a person with
metastatic medulloblastoma.
In 2002, a 25-year-old woman was referred to our
institution for relapsed medulloblastoma (stage IV, World
Health Organization Classiﬁcation) and was previously
treated with radical surgery and adjuvant craniospinal
radiotherapy. The patient had grade IV thrombocytopenia
and grade III anemia requiring RBC transfusions.
Complete restaging documented medulloblastoma BM
involvement by trephine core biopsy and no other sites of
recurrence. The patient was given conventional chemother-
apy (CY, etoposide and cisplatin) with a clinical beneﬁt
(progressive reduction in transfusion requirement – Figure 1)
and biopsy-proven persistence of BM involvement
(Figures 2a–c). Because of the poor prognosis of recurrent
medulloblastoma with expected short-term survival and
the lack of alternative therapeutic option (intensiﬁed
chemotherapy with autologous stem cell support5 was
excluded owing to marrow involvement), the patient
gave written informed consent to be treated according to
a phase I NST protocol for refractory solid tumors
approved by the Ethical Committee of Ospedale Niguarda
Ca’ Granda.6
In March 2003, the patient received a pre transplant
conditioning regimen consisting of IV thiotepa (300mg/m2)
on day 5, CY (30mg/kg daily) and ﬂudarabine (30mg/m2
daily) on days 4 and 3. On day 0, 6.62 106 ﬁlgrastim
mobilized CD34þ cells and 4.4 108 CD3þ cells/kg
recipient, collected from the 25-year-old HLA identical brother,
were transplanted into the patient.7 Immunosuppression
for GVHD prophylaxis consisted of CYA and short-course
MTX. Antimicrobial therapy followed institutional
protocols consisting of itraconazole for antifungal
prophylaxis, acyclovir for antiviral prophylaxis and
levoﬂoxacin for antibacterial prophylaxis. The degree of
donor–recipient chimerism in both myeloid and T-cell
lineages was assessed by PCR assay of minisatellite regions.
Hematopoietic engraftment was achieved on day þ 13,
and early post transplant course was uneventful. CYA
administration was tapered and discontinued on day þ 80,
in the absence of acute GVHD and with 100% T-cell donor
chimerism, which was conﬁrmed on subsequent controls.
BM biopsy performed on day þ 120 (Figures 2b–d) showed
CR of medulloblastoma inﬁltration. On day þ 110, 30 days
after discontinuation of CYA, she developed grade II/III
hepatic GVHD that was conﬁrmed by liver biopsy. The
patient was treated with steroids and extracorporeal
photopheresis8 with full recovery. Six months following
transplant, she developed extensive chronic cutaneous and
mucosal GVHD. Oral prednisone and subsequently CYA
were given and since then she has required immunosup-
pressive treatment at doses depending on the clinical
behavior of GVHD. In August 2006, the patient developed
muscle weakness; antinuclear antibody test result elevated
(41:640) and musculoskeletal biopsy allowed for the
diagnosis of dermatomyositis. Low-dose MTX was intro-
duced with muscle strength improvement and normal-
ization of antinuclear antibody test. At present,
approaching 5 years from NST, the patient is in CR, with
extensive chronic cutaneous GVHD requiring immuno-
suppressive therapy.
Because of the poor prognosis of recurrent metastatic
medulloblastoma,9 the long-lasting remission obtained in
this patient can only be attributed to the antitumor effect
generated by the donor’s immune system. Unfortunately,
the graft-versus tumor effect was associated with the
occurrence of chronic GVHD, a complication that, as in
this case, can signiﬁcantly impair patient’s quality of life.
We believe that this pilot treatment experience suggests
that NST is an approach to be considered for selected
patients with relapsed metastatic medulloblastoma and an
otherwise poor prognosis who have an HLA identical
sibling. This is also in light of most recent advances in the
prophylaxis and treatment of GVHD.10
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Figure 1 Normalization of RBC and platelet counts in peripheral blood and reversal of RBC transfusion requirements after non-myeloablative allogeneic
hematopoietic SCT. Hb levels refer to the lowest levels before RBC transfusion. Each black arrow refers to two packed RBC units.
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Figure 2 Microscopic evaluation of BM biopsies before (a and c) and 4 months after allogeneic hematopoietic SCT (b and d). Panels a and c show
medulloblastoma cell inﬁltration assessed by standard hematoxylin–eosin and glial ﬁbrillary acidic protein immunohistochemistry stain, respectively. Panels
b and d show normal hematopoietic cells and lack of BM inﬁltration by medulloblastoma cells assessed by the same methods of panels a and c, respectively.
Figures show representative ﬁelds at  200 (a and b) or  400 (c and d) magniﬁcations.
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